Kiromic BioPharma, Inc. has had a tricky time so far, having had to close a handful of clinical trials of its T-cell therapies owing to poor patient accrual and undergoing delisting from the NASDAQ last September. But now it has reported data on the first two patients in a clinical trial in lung cancer and Deltacel, an allogeneic gamma-delta T-cell product, looks promising.
Key Takeaways
- Kiromic BioPharma is developing a gamma-delta T-cell therapy for lung cancer
- Definitive Phase I data could come in December
- The company hopes a successful therapy will help...
“We had high confidence about what this product will be able to deliver. And so far, we can say that we were right,” Pietro Bersani, the group’s CEO, told Scrip....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
